At Home BERN BIO Continue BIO Guard-MI BIO Women BIO|CONCEPT.BIOMONITOR III BIOFLEX-I BIOFLOW-I BIOFLOW-II BIOFLOW-III BIOFLOW-V BIOLUX P-I BIOLUX P-II BIO-RESORT BIOSCIENCE BIOSOLVE-I BIOSOLVE-II BIOSync CLS Castle-AF CELESTIAL COMPAS DEBAS-I DELUX EchoCRT ECOST ENERGY GALAXY HoMASQ IMPACT IN-TIME ISAR-DESIRE 4 KURT Et Al. (2018) Matrix NORDIC-ICD ORIENT PEACE PEBSI PEPPER ProMRI (Phase B) ProMRI (Phase C) ProMRI AFFIRM Protego QP ExCELs QP ExCELs (CRT-DX) Replace RM-ALONE SCAAR SELENE HF SENSE SIELLO SORT OUT VII TASC D II TASC D Registry THINGS TRUECOIN TRUST CONFERENCES AND EVENTS DIGITAL CUSTOMER EDUCATION DEVICE EXPERT APP PRODUCT PERFORMANCE CENTER PROGRAMMER SOFTWARE CYBERSECURITY TECHNICAL LIBRARY PRODUCTS CAREERS NEWSROOM CONTACT EN BIO-RESORT RCT NCT01674803 Comparison of biodegradable polymer and durable polymer drug-eluting stents in an all comers population Downloads Conclusion In this 3514 patient large, randomized, investigator-initiated, all-comers trial, Orsiro proves non-inferiority to Resolute Integrity whilst performing equally well as Synergy (primary endpoint TVF at 12 months: Orsiro 4.7%, Synergy 4.7%, Resolute Integrity 5.4%, p non-inferiority < 0.0001) Orsiro, with its ultrathin struts and bioabsorbable polymer, additionally showed safety with a definite stent thrombosis rate of 0.3 % at 12 months, which was equally low in the other study arms. These convincing results reconfirm those of previous Orsiro trials and adds to the solid foundation of clinical evidence that supports the use of Orsiro across a broad range of applications. Study Design All-comers, multi-center, assessor and patient-blinded, randomized, non-inferiority design Principal Investigator: Prof. Clemens von Birgelen, Enschede, Netherlands Primary endpoint: Target Vessel Failure (TVF) at 12 months defined as the composite of cardiac death, target vessel-related Myocardial Infarction (MI), or Target Vessel Revascularization (TVR) Prespecified secondary endpoints: Components of the primary endpoint, All-cause mortality, Any Myocardial Infarction, Clinically indicated TLR, Stent thrombosis Image Primary endpoint results Target vessel failure1,2 Image Downloads BIO-RESORT Clinical Study Flyer VASCULAR INTERVENTION Orsiro Drug-Eluting Stent VASCULAR INTERVENTION ORIENT Clinical Study Disclaimer © BIOTRONIK AG – All rights reserved. Specifications are subject to modification, revision and improvement. 1 von Birgelen C et al. BIO-RESORT (TWENTE III). A Prospective, Randomized Three-Arm Trial Comparing Orsiro, Synergy and Resolute Integrity in an All-Comers Population. TCT 2016. Oral presentation. 2 von Birgelen C et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet 2016. Online publication (10.1016. S0140-6736(16); 31920-1). FOLLOW US TWITTER YOUTUBE LINKEDIN LEARN MORE ORSIRO 360°CRT HEART MONITORING MAGMARIS HOME MONITORING SERVICE CENTER GENERAL TERMS AND CONDITIONS COOKIE SETTINGS IMPRINT LEGAL DISCLAIMER PRIVACY STATEMENT